

# Synaptic P2X<sub>7</sub> and Oxygen/Glucose Deprivation in Organotypic Hippocampal Cultures

\*Fabio Cavaliere, \*†Susanna Amadio, \*†Giuseppe Sancesario, \*†Giorgio Bernardi, and  
\*‡§Cinzia Volonté

\*Fondazione Santa Lucia, Rome, Italy, †University of Rome Tor Vergata, Department of Neuroscience, ‡C.N.R. Institute of Neurobiology and Molecular Medicine, Rome, Italy.

**Summary:** The P2X<sub>7</sub> receptor for extracellular ATP is the main candidate, among P2 receptors, inducing cell death in the immune system. Here, we demonstrate the direct participation of this receptor to cell damage induced by oxygen/glucose deprivation, in the *ex vivo* model of organotypic hippocampal cultures. By pharmacological and immunological approaches, we show that P2X<sub>7</sub> is rapidly and transiently up regulated in hippocampal areas eliciting metabolism impairment. Moreover, the P2 antagonists 2',3',-dialdehyde ATP and reactive blue 2 prevent both up regulation of this receptor and hypoxic/hypoglycemic damage. By confocal laser microscopy, we show that P2X<sub>7</sub> is present at the synaptic level of fibers extending from the CA1–2 pyramidal cell layer throughout the strata oriens and radiatum, but absent on oligodendrocytes, as-

trocytes or neuronal cell bodies. Colocalization of P2X<sub>7</sub> is obtained with neurofilament-L protein and with synaptophysin, not with myelin basic protein, glial fibrillary acidic protein or a marker for neuronal nuclei. P2X<sub>7</sub> up regulation and diffuse cellular damage are also induced by 3'-O-(4-benzoyl) benzoyl-ATP, an agonist selective but not exclusive for P2X<sub>7</sub>.

In summary, our study demonstrates that P2X<sub>7</sub> not only directly participates to the hypoxic/hypoglycemic process, but also owns specific phenotypic localization. We do not exclude that it might serve as a sensor of dysregulated neuronal activity and ATP release, both occurring during oxygen/glucose deprivation. **Key Words:** Ischemia—P2 receptors—oxATP—BzATP—Synaptophysin—Neurofilament.

ATP is now regarded as one of the most ubiquitous neuromodulator co-released in the extracellular space together with other neurotransmitters such as glutamate or acetylcholine and acting as an intercellular signaling molecule (Burnstock and Williams, 2000; Fields and Stevens, 2000; Vizi, 2000).

The receptors for extracellular ATP are classified into P2X and P2Y subclasses. P2Y are G-protein coupled metabotropic receptors possessing slow excitatory responses. P2X are ionotropic receptors responsible for fast excitatory neurotransmission (North and Barnard,

1997). These last are in turn classified by electrophysiological properties and molecular homology into seven different subunits (P2X<sub>1–7</sub>) (Khakh et al., 2001), which are functional only when assembled in heteromeric and oligomeric structures. For example, P2X<sub>2</sub> can dimerize with P2X<sub>3</sub>, and P2X<sub>1</sub> (Nicke et al., 1998) can form active receptors with P2X<sub>5</sub> (North, 2002). On the contrary, P2X<sub>7</sub> is the only receptor to be functional in its homomeric form (North and Surprenant, 2000). The P2X<sub>7</sub> is also considered the most cytotoxic among P2 receptors. Although it is widely expressed in a variety of different tissues (Collo et al., 1997), its role on cellular toxicity and inflammation was thoroughly studied in the immune system (Di Virgilio et al., 1995; Di Virgilio et al., 1999). Stimulation of P2X<sub>7</sub> with ATP induces a plethora of biological responses comprising intracellular Ca<sup>++</sup> overloading and K<sup>+</sup> efflux, all culminating with apoptotic and necrotic cell death (Schulze-Lohoff et al., 1998; Chen and Swanson, 2003). Recently, it was also suggested that activation of P2X<sub>7</sub> regulates the release of neurotransmitters in astrocytes and neurons (Duan et al., 2003; Sperlagh et al., 2002) and the cleavage and release of IL-1 in macrophages and microglia (Sanz and Di Virgilio, 2000;

Received July 16, 2003, revised October 3, 2003; accepted December 5, 2003.

The research presented was supported by the Italian Health Ministry, project number RA00.86V and by Cofinanziamento MURST 2001–2002.

§Address correspondence and reprint requests to Cinzia Volonté, Fondazione Santa Lucia, Via Ardeatina 354, 00179 Rome, Italy; e-mail: cinzia@in.rm.cnr.it

**Abbreviations used:** BzATP, 3'-O-(4-benzoyl) benzoyl ATP; CLSM, confocal laser scanning microscope; DIV, days *in vitro*; GFAP, glial fibrillary acidic protein; IL-1β, interleukin 1 beta; MBP, myelin basic protein; NeuN, marker for neuronal nuclei; NFL, neurofilament-L protein; OxATP, 2',3',-Dialdehyde ATP; PI, propidium iodide; RB-2, reactive blue 2; Syn, synaptophysin.

Le Feuvre et al., 2002; 2003). These events leading to cell death comprise phosphorylation and activation of specific kinases (Parvathani et al 2003; Humphreys et al., 2000; Communi et al., 1999) and induction of transcription factors (Ferrari et al. 1997) and caspase-1 (Ferrari et al. 1999; Shulze-Lohoff et al., 1998).

In contrast, little is still known about the exact function of the P2X<sub>7</sub> in neurons and its involvement in neurodegenerative insults and stroke, although preliminary results were reported. For instance, during an ischemic event ATP may reach high extracellular levels, being exocytotically released from various cell types including neurons (Agteresch et al., 1999). Moreover, Collo and her colleagues (1997) demonstrated that P2X<sub>7</sub> mRNA expression increases in the penumbra of ischemic damage; Amadio et al. (2002) reported that P2X<sub>7</sub> mRNA and protein are up regulated in cerebellar granule neurons and in hippocampal organotypic cultures following ATP stimulation; Cavaliere et al. (2002) showed that P2X<sub>7</sub> protein augments as a consequence of metabolism impairment in CNS neurons. Since in a previous work we described that P2X<sub>2</sub> and P2X<sub>4</sub> are up regulated, respectively in neurons and in microglia, by transient global ischemia in the gerbil (Cavaliere et al., 2003), in this work we analyze the participation of the P2X<sub>7</sub> receptor to oxygen/glucose deprivation, using the *ex vivo* model of organotypic primary hippocampal cultures.

## METHODS

### Organotypic cultures

Organotypic hippocampal slice cultures were prepared using a modification of the method by Stoppini (1991). Briefly, Wistar rat pups (8–10 days old) were sacrificed and brains removed. Hippocampi were excised, cut on a Mc Ilwain tissue chopper (400 μm) and the slices separated into cold HBSS (0.185 mg/ml CaCl<sub>2</sub>, 0.1 mg/ml MgSO<sub>4</sub>, 0.4 mg/ml KCl, 0.06 mg/ml KH<sub>2</sub>PO<sub>4</sub>, 8 mg/ml NaCl, 0.05 mg/ml Na<sub>2</sub>HPO<sub>4</sub>, 0.35 mg/ml NaHCO<sub>3</sub>, 1 mg/ml glucose; Sigma, MI-Italy). Four slices were plated on each Millicell CM culture inserts (Millipore Rome, Italy) and kept in organotypic maintenance medium (50% MEM, 25% HBSS, 25% heat-inactivated horse serum, supplemented with 4.5 mg/ml glucose, 1 mM glutamine) at 37°C, 100% humidity and 5% CO<sub>2</sub>. The medium was changed every 3–4 days and experiments performed after 12–14 days *in vitro*.

### Oxygen/glucose deprivation and quantification of cell death

For oxygen/glucose deprivation studies, the Millicell CM inserts with organotypic slices were placed for 40–60 minutes at 37°C in a N<sub>2</sub> saturated environment in 1 ml of Glucose-Free Medium (GFM-Earle's Balanced Salt Solution; Sigma, MI-Italy) added with 5 μg/ml propidium iodide (PI), previously saturated with 95% N<sub>2</sub>, for the analysis of cell death. The GFM was then replaced with the organotypic maintenance medium and the cultures were kept with 5 μg/ml PI under normoxic conditions for different lengths of time, before evaluating cell death. For normoxic conditions, the medium consisted of GFM supplemented with 1 mg/ml of glucose.

The extent of cell death was quantified by propidium iodide incorporation measured with a fluorescence microscope, using the densitometry software Scion Image for Windows (Scion corporation, Maryland, USA), obtained from the NIH public domain. In detail, regions of interest (ROI) from each experimental image were outlined and pixel/inches were directly measured, following the software procedures directly provided by the manufacturer. Results are expressed as mean pixel/inches ± SEM (n = 3).

### Total protein extraction from organotypic cultures

Organotypic cultures were maintained for 40 minutes under oxygen/glucose deprivation. After different lengths of post-treatment time, four organotypic slices were extracted in RIPA buffer (PBS supplemented with 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 μM PMSF, 10 μg/ml leupeptin, all from Sigma, MI-Italy) and homogenized. They were maintained for one hour on ice, sonicated and centrifuged at 4°C at 10000x g for 10 minutes. Protein quantification was performed in the supernatants by Bradford colorimetric assay (Biorad, MI-Italy).

### Western blot


Equal amount of total protein from each sample (50 μg) was separated by SDS-PAGE on a 12% polyacrylamide gel and transferred over-night onto a nitrocellulose membrane Hybond C (Amersham, MI-Italy). The filters were pre-wetted in 5% non-fat milk in TBS-T (10 mM Tris pH 8, 150 mM NaCl, 0.1% Tween 20) and hybridized for three hours with anti-P2X<sub>1,4,7</sub> antisera (1:200) (Alomone, Jerusalem, Israel). All antisera were immunodetected with an anti-rabbit HRP conjugated antibody and developed by ECL chemiluminescence (Santa Cruz, MI, Italy). Quantification of the specific bands was performed in a linear range of detection, by using Kodak 1D 3.5.3 software.

### Immunofluorescence studies

**Confocal microscopy.** Organotypic hippocampal slices were used for immunofluorescence labeling. Each slice was fixed for 2.5 hours at RT in 4% para-formaldehyde, three times washed in PBS and then incubated in a mixture of primary antisera for 24 hours in 0.4% Triton X-100 in 1% albumin bovine serum in PBS. Rabbit anti-P2X<sub>7</sub> (1:100, Alomone, Jerusalem-Israel) was used alone or in combination with mouse anti-MBP (myelin basic protein, 1:400, Boehringer Mannheim, MI-Italy), mouse anti-GFAP (glial fibrillary acidic protein, 1:400, Sigma, MI-Italy), goat anti-NFL (neurofilament-L protein, 1:100, Santa Cruz, MI-Italy) or mouse anti-synaptophysin (1:100 Sigma, MI-Italy). The secondary antibodies were Cy2-conjugated donkey anti-rabbit IgG (1:100, green immunofluorescence) or Cy3-conjugated donkey anti-mouse IgG (1:100, red immunofluorescence) or Cy3-conjugated donkey anti-goat IgG (1:100, red immunofluorescence). All antibodies were from Jackson ImmunoResearch, West Baltimore Pike PA, USA. The sections were washed three times in PBS for five minutes and then incubated for 2 hours with the secondary antibodies. After rinsing, the slices were mounted on slide glasses, allowed to air dry and cover slipped with gel/mount™ anti-fading medium (Biomedica, Foster City CA, USA).

Double label immunofluorescence was analyzed by means of a confocal laser scanning microscope (CLSM) (LSM 510, Zeiss, MI-Italy) equipped with an argon laser emitting at 488 nm and a helium/neon laser emitting at 543 nm.

**Statistical analysis.** Values were normalized as specified in each figure legend. Statistical differences were evaluated by



**FIG. 1.** The P2X<sub>7</sub> antagonist oxATP protects from hypoxic/hypoglycemic hippocampal injury and prevents P2X<sub>7</sub> protein up regulation. Hippocampal organotypic cultures at 12–14 DIV were maintained for 40 minutes under oxygen/glucose deprivation (OGD), in the simultaneous presence or absence of 100  $\mu$ M 2',3',-Dialdehyde ATP (oxATP). Control cultures (CTRL) were maintained in the presence of 1 mg/ml glucose. Cellular damage was visualized 20 hours later with a fluorescence microscope, by propidium iodide incorporation (A). Immunofluorescence for P2X<sub>7</sub> receptor was performed in 1 hour after oxygen/glucose deprivation and visualized at 20X magnification (B). The results were analyzed by using Scion Image and are representative of three independent experiments. Intensities are expressed as mean pixel/inches  $\pm$  SEM ( $n = 3$ ), where n.d. (not detected) represents a signal below threshold level. Statistical differences in OGD were calculated vs CTRL, whereas in OGD+oxATP they were calculated vs OGD.

one-way analysis of variance (ANOVA), followed by post hoc test (HSD Tukey). A value of  $P < 0.05$  is considered significant.


## RESULTS

In this work, we adopted organotypic slice cultures to study the direct participation of the P2X<sub>7</sub> receptor to the cellular damage caused by oxygen/glucose deprivation, using both pharmacological and immunological approaches. We deprived the organotypic hippocampal slices of oxygen/glucose for 40 minutes respectively in the absence or presence of the specific P2X<sub>7</sub> antagonist 2',3',-dialdehyde ATP (oxATP) (Fig. 1A) (Murgia et al., 1993). Under these conditions, a localized CA1–3 cellular damage (Frantseva et al., 2002; Pringle et al., 1997) was obtained in about 20 hours post-treatment (Fig. 1A). As visualized by propidium iodide incorporation, whereas the simultaneous addition of 100  $\mu$ M oxATP during oxygen/glucose deprivation only partially reduced the cellular damage in the CA1–3 hippocampal region (data not shown), oxATP completely sustained cell viability when provided 1 hour before and during hypoxia/hypoglycemia (Fig. 1A).


We also studied the P2X<sub>7</sub> protein expression following metabolism impairment. In 1 hour after the insult (Fig. 1B), the P2X<sub>7</sub> immunofluorescent signal homogeneously

increased (about two fold) in the treated slices compared to the control, whereas the antagonist oxATP reduced this effect by about 70% (Fig. 1B). When observed at higher magnification, immunofluorescence was present especially on parallel fibers running across the pyramidal cell layer at the CA1–2 region (Fig. 3B and Fig. 4). Confirming this up regulation, Western blot analysis showed a strong transient induction of the P2X<sub>7</sub> protein occurring in 1 hour post-treatment (Fig. 2A). This decreased to control level in 20 hours, when the cellular damage was instead maximally induced (Fig. 1A). When added before and during oxygen/glucose deprivation, 100  $\mu$ M oxATP not only reduced the cellular damage (Fig. 1A), but also partially prevented (about 55%) the induction of the P2X<sub>7</sub> protein (Fig. 2B). The broadly effective P2 antagonist Reactive Blue-2 (Cavaliere et al., 2001a; Cavaliere et al., 2001b) completely inhibited such up regulation (Fig. 2B).

We localized the P2X<sub>7</sub> signal by performing double labeling with propidium iodide. In one hour after the insult, the incorporation of propidium iodide starting in the CA1–2 region overlapped with the P2X<sub>7</sub> staining (Fig. 3A; 20X magnification). Nevertheless, ultra structural analysis at higher magnification did not reveal colocalizing signals between P2X<sub>7</sub> and cellular damage (Fig. 3B; 40X magnification). In one hour after




**FIG. 2.** Expression of P2X<sub>7</sub> receptor after hypoxia/hypoglycemia: Western blot analysis. Hippocampal organotypic cultures at 12–14 DIV were maintained for 40 minutes under oxygen/glucose deprivation (OGD). Total protein was extracted after different lengths of time (A) and analyzed by Western blot in the absence (no add) or presence of 100  $\mu$ M oxATP or 100  $\mu$ M reactive blue 2 (RB-2) (B). Similar results were obtained in three independent experiments. Bands were quantified with Kodak Image Station software, and expressed as arbitrary units. Statistical differences were calculated by one-way ANOVA test followed by Tukey's *post hoc* test. Statistical differences were evaluated as follow: in (A), OGD post treatment was compared to ctrl; in (B), no add was compared to ctrl; both oxATP and RB-2 were compared to no add. (\*\*\*) $P < 0.001$ ; (###) $P < 0.001$ ; (##) $P < 0.01$ .



**FIG. 3.** Up regulation of P2X<sub>7</sub> protein occurs in 1 hour post-treatment in the CA1–2 damaged region. Organotypic slices were subjected to oxygen/glucose deprivation for 40 minutes and to 1 hour post-treatment, in the presence of 5  $\mu$ g/ml of propidium iodide. The slices were then fixed and stained with anti-P2X<sub>7</sub>. Results are representative of at least three independent experiments.


oxygen/glucose deprivation, the P2X<sub>7</sub> immunopositive signal was present on green punctuated fibers extending throughout the CA1–CA2 pyramidal cell layer, but was not coincident with the nuclear staining observed with propidium iodide (Fig. 3B merged view). At a cellular level, we demonstrated that the P2X<sub>7</sub> positive signal did not colocalize with neuronal nuclei (Fig. 4A), with oligodendrocytes (Fig. 4B), or with astrocytes (Fig. 4C). We instead described both neuronal localization of P2X<sub>7</sub>




**FIG. 4.** Cellular localization of P2X<sub>7</sub> receptor protein. After 40 minutes of oxygen/glucose deprivation and 1 hour post-treatment, hippocampal organotypic cultures were double stained with P2X<sub>7</sub> and several cellular markers. The CA1–2 region was visualized by CLSM. Antibodies against NeuN were used for labeling neuronal nuclei; against myelin basic protein (MBP) for oligodendrocytes, and against glial fibrillary acidic protein (GFAP) for astrocytes. Results are representative of three independent experiments.

on fibers sprouting from the pyramidal cell layer to the strata oriens and radiatum (Figs. 1B, 3A, 4A) as well as positive double staining with neurofilament-L protein (NFL) (Fig. 5A). Moreover, as shown in Fig. 5B, double immunofluorescence demonstrated strong colocalization between P2X<sub>7</sub> and the synaptic marker synaptophysin.

In order to strengthen the correlation between P2X<sub>7</sub> and cell death, we subjected hippocampal slices to 3'-O-(4-benzoyl) benzoyl ATP (BzATP) and then tested cellular damage and P2X<sub>7</sub> protein expression. Although very limited subtype-specific P2 ligands yet exist and most available agonists/antagonists generally bind to both P2X and P2Y subclasses (Burnstock, 2002), the compound BzATP is a P2 agonist considered most specific for P2X<sub>7</sub> although activating a few additional P2X receptors (P2X<sub>1,3,4</sub>) (North and Surprenant, 2000; Evans et al., 1995). Therefore, we kept the organotypic hippocampal cultures with 500  $\mu$ M BzATP for 20 hours, in the presence or absence of the P2X<sub>7</sub> specific antagonist ox-ATP. We observed diffuse cell death without specific damage across the entire hippocampal region, and a reduction by oxATP of about 40% in the propidium iodide incorporation (Fig. 6A). Under these conditions, also the



**FIG. 5.** Sub-cellular localization of P2X<sub>7</sub> receptor protein. After oxygen/glucose deprivation, the hippocampal slices were fixed, double stained with P2X<sub>7</sub> and either neurofilament-L protein (NFL) (A) or synaptophysin (Syn) (B), and CA1–2 region was visualized by CLSM (40X magnification). In (A), the arrows show a marked colocalization of P2X<sub>7</sub> and NFL; in (B), the white square on the merged panel is enlarged at 100X magnification and the asterisk indicates the neuronal bodies. Results are representative of three independent experiments.



**FIG. 6.** BzATP-induced damage and modulation of P2X target receptors. (A) Hippocampal organotypic cultures at 12–14 DIV were maintained for 20 hours in maintenance medium, in the presence of 500  $\mu$ M BzATP and with or without 100  $\mu$ M oxATP. Cellular damage was visualized with a fluorescence microscope by propidium iodide incorporation. Results are representative of three independent experiments and were analyzed by using Scion Image. Intensities are expressed as mean pixel/inches  $\pm$  SEM ( $n = 3$ ), where n.d. (not detected) represents a signal below threshold level. Statistical differences in BzATP were calculated vs CTRL, whereas in BzATP+oxATP they were calculated vs BzATP. (B) Organotypic cultures were homogenized, total protein was extracted and P2X<sub>1,7</sub> was detected by Western blot and analyzed by Kodak software. Statistical differences were calculated in sample 2 (BzATP) vs 1 (CTRL), and in sample 3 (BzATP+oxATP) vs 2 (BzATP). (\*\*\* $P < 0.001$ ; \*\* $P < 0.01$ ; ## $P < 0.01$ ; # $P < 0.05$ ).

P2X<sub>7</sub> protein expression was induced by BzATP (about 100%) and prevented by oxATP (60% reduction), as demonstrated by Western blot analysis and quantification (Fig. 6B). In parallel, we observed about two/three fold increase in the P2X<sub>1</sub> protein expression, but this was not prevented by oxATP (Fig. 6B) thereby confirming the specificity of oxATP on P2X<sub>7</sub>. The additional targets of BzATP, P2X<sub>3</sub> and P2X<sub>4</sub>, were not modulated in protein expression during and after the insult (data not shown).

## DISCUSSION

The use of organotypic slice cultures represents one of the most convenient *ex vivo* system to study features and mechanisms of cerebral hypoxia/hypoglycemia (Pringle et al., 1997; Pellegrini-Gianpietro et al., 1999). The slices preserve organotypic structures and functions, neuron-glia interactions and activation of numerous pathways, such as immune and inflammatory responses (Coltman et al., 1995; Czapiga and Colton, 1999). Moreover, they represent an efficient biological model to overcome the

*in vivo* impediments of the blood brain barrier. Our previous work demonstrated, both in organotypic cultures and *in vivo*, the direct participation of the extracellular ATP receptors, particularly P2X<sub>2</sub> (over expressed in neurons) and P2X<sub>4</sub> (over expressed in microglia), to ischemic injury (Cavaliere et al., 2003). Whereas little is still known about a direct role of P2X<sub>7</sub> on metabolic impairment, indirect experimental evidence is provided by the outflow of ATP from damaged cells after seizure and stroke (Nieber et al., 1999; Phillis et al., 1993; Burnstock 2002), by the expression of P2X<sub>7</sub> in different cell types, tissues and in the penumbra of ischemic damage (Collo et al., 1997; Di Virgilio et al., 1995; Di Virgilio et al., 1999), by the increase of microglial P2X<sub>7</sub> mRNA and protein during cerebral ischemia in a rodent model (Collo et al., 1997), and by the activation and modulation of inflammatory processes through several P2 receptors comprising P2X<sub>7</sub> (Di Virgilio 1995; North, 2002). With the present work, we now recognize the ionotropic P2X<sub>7</sub> receptor as an important element in the mechanisms of cellular damage induced by oxygen/glucose deprivation. On this topic, Le Feuvre and co-workers recently established a distinction between *in vitro* and *in vivo* pro-inflammatory role of P2X<sub>7</sub> following ischemic insults (Le Feuvre et al., 2002; 2003). Although they demonstrated that activation of P2X<sub>7</sub> in primary *in vitro* cultures of microglia and macrophages directly regulates the release of IL-1 (Brough et al., 2002), they sustained that pathways additional or parallel to P2X<sub>7</sub> receptor could mediate IL-1 secretion in *in vivo* ischemia. In fact, deletion of P2X<sub>7</sub> in knock out mice does not apparently affect neuronal damage induced in the cortex-striatum by medial cerebral artery occlusion (Le Feuvre et al., 2002), and a selective antagonist of IL-1 receptor reduces the ischemic damage also in P2X<sub>7</sub> knock out mice (Le Feuvre et al., 2003).

Our *ex vivo* model of hippocampal organotypic cultures now establishes that the insult from oxygen/glucose deprivation goes also through the neuronal P2X<sub>7</sub> receptor. Pharmacological data integrate and support biochemical and immunological evidence on this regard. We have first demonstrated that during the early phases of post-hypoxia/hypoglycemia, before the onset of cell loss, the P2X<sub>7</sub> protein is rapidly and transiently activated. Moreover, P2X<sub>7</sub> can be considered an early marker of a specifically localized cellular damage. In fact, up regulation occurs in hippocampal areas coincident with cellular damage and specific (oxATP) or widespread (RB-2) P2 receptor antagonists either reduce or block simultaneously this activation and cellular damage. Second, we have proved that despite a temporal gap between P2X<sub>7</sub> induction and cell loss, the topological and pharmacological correlation between P2X<sub>7</sub> expression and cell death is very specific. Whereas hypoxia/hypoglycemia induce cell death in the restricted

CA1–3 hippocampal region, BzATP causes a more largely diffuse cellular damage in the entire hippocampal area. Furthermore, the selective P2X<sub>7</sub> antagonist oxATP totally prevents cell death, but only partially reduces the cell damage caused by BzATP. In this case, the less localized insult and the consequent less efficient protection would suggest that pathways additional to P2X<sub>7</sub> might be involved. Indeed, our results show that P2X<sub>1</sub> is already a likely candidate, being up regulated by BzATP but not inhibited by oxATP. This is consistent with the concept that factors additional to ATP, such as IL-1 (Brough et al., 2002) or TNF $\alpha$  (Hide et al., 2000), and receptors additional to P2X<sub>7</sub>, such as P2X<sub>2</sub> and P2X<sub>4</sub> (Cavaliere et al., 2003), might be actively involved. Indeed, if metabolic impairment certainly occurs through the induction and activity of the P2X<sub>7</sub> receptor, we do not exclude that complementary redundant receptors might be simultaneously recruited or compensatory mechanisms might be triggered (Cavaliere et al., 2001a,b).

In this work, we also characterized the cellular and sub cellular distribution of P2X<sub>7</sub> in hippocampal sections after oxygen/glucose deprivation. Not only this receptor specifically takes part in the metabolic impairment, it also owns specific phenotypic targets. The P2X<sub>7</sub> signal is in fact present in fibrillary and parallel structures rising from the damaged region to the strata oriens and radiatum. Whereas absent in oligodendrocytes, astrocytes and neuronal cell bodies, it is instead localized in neurites at the synaptic level. This confirms the work by Sperlagh et al (2002) and Armstrong and colleagues (2002), which demonstrates the presynaptic localization of P2X<sub>7</sub> in the CA1-CA3 region. Therefore, we could speculate that P2X<sub>7</sub> present at the presynaptic membrane might serve as a sensor of dysregulated neuronal activity and ATP release, which both occur during oxygen/glucose deprivation. These events might in turn detrimentally over stimulate the P2X<sub>7</sub> receptor, which is already known to require high doses of ATP to be activated (North and Surprenant, 2000). This would also explain the strong up regulation of P2X<sub>7</sub> occurring only during the early stages of the hypoxic/hypoglycemic insult, when ATP is maximally released (Juranyi et al., 1999). Changes in receptor number are actually a well-studied mechanism for activity-dependent changes in synaptic efficacy.

Another important issue emerging from our study is the involvement of P2X<sub>7</sub> either in neurodegenerative events or in regenerative efforts. Since P2X<sub>7</sub> seems not to be present on neuronal cell bodies, on differentiated cells such as astrocytes and oligodendrocytes present at the injury site, it is likely that its up regulation and presence at synaptic terminals could be coincident with the neuronal activity occurring through the injury. This may in turn be related to the ability of the ischemic tissue to undergo intercalary modulation toward both degenera-

tion and regeneration. The most appealing question is now to understand in which of these opposite situations exactly the P2X<sub>7</sub> receptor fills in, if not in both.

Finally, ischemic injury still maintains unanswered fundamental questions. The challenge remains not only to understand all the propagating mechanisms, but also to identify all the players. Our work contributes to reveal that the P2X<sub>7</sub> receptor directly takes part to the metabolic impairment and that the cellular events, which are observed *ex vivo* to be mediated by the P2X<sub>7</sub> during hypoxia/hypoglycemia, could contribute to the remodeling of the cellular functions seen *in vivo*.

**Acknowledgment:** The professional style editing of Mrs. Catherine Wrenn is gratefully acknowledged. We thank Dr. C. Sgobio for support on statistical analysis of the data.

## REFERENCES

- Agteresch HJ, Dagnelie PC, van den Berg JW, Wilson JH (1999) Adenosine triphosphate: established and potential clinical applications. *Drugs* 58, 211–232
- Amadio S, D'Ambrosi N, Cavaliere F, Murra B, Sancesario G, Bernardi G, Burnstock G, Volontè C (2002) P2 receptor modulation and cytotoxic function in cultured CNS neurons. *Neuropharmacol* 42, 489–501
- Armstrong JN, Brust TB, Lewis RG, MacVicar BA (2002) Activation of presynaptic P2X<sub>7</sub>-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. *J Neurosci* 22:5938–5945
- Brough D, Le Feuvre RA, Iwakura Y, Rothwell NJ (2002) Purinergic (P2X<sub>7</sub>) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. *Mol Cell Neurosci* 19:272–280
- Burnstock G (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling. *Clin Med* 2:45–53
- Burnstock G, Williams M (2000) P2 purinergic receptors: modulation of cell function and therapeutic potential. *J Pharmacol Exp Ther* 295:862–869
- Cavaliere F, D'Ambrosi N, Ciotti MT, Mancino G, Sancesario G, Bernardi G, Volontè C (2001a) Glucose deprivation and mitochondrial dysfunction: neuroprotection by P2 receptor antagonists. *Neurochem Int* 38, 189–197
- Cavaliere F, D'Ambrosi N, Sancesario G, Bernardi G, Volontè C (2001b) Hypoglycaemia-induced cell death: features of neuroprotection by the P2 receptor antagonist basilen blue. *Neurochem Int* 38:199–207
- Cavaliere F, Sancesario G, Bernardi G, Volontè C (2002) Extracellular ATP and nerve growth factor intensify hypoglycemia-induced cell death in primary neurons: role of P2 and NGFRp75 receptors. *J Neurochem* 83:1129–1138
- Cavaliere F, Florenzano F, Amadio S, Fusco FR, Viscomi MT, D'Ambrosi N, Vacca F, Sancesario G, Bernardi G, Molinari M, Volontè C (2003) Up regulation of P2X<sub>2</sub>, P2X<sub>4</sub> receptor and ischemic cell death: prevention by P2 antagonists. *Neurosci* 120:85–98
- Chen Y, Swanson RA (2003) Astrocytes and brain injury. *J Cereb Blood Flow Metab* 23:137–149
- Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G (1997) Tissue distribution of the P2X<sub>7</sub> receptor. *Neuropharmacol* 36:1277–1283
- Coltman BW, Earley EM, Shahar A, Dudek FE, and Ide CF (1995) Factors influencing mossy fiber collateral sprouting in organotypic slice cultures of neonatal mouse hippocampus. *J Comp Neurol* 362:209–222
- Communi D, Dewaste V, Erneux C (1999) Calcium-calmodulin-dependent protein kinase II and protein kinase C-mediated phosphorylation and activation of D-myo-inositol 1,4, 5-trisphosphate 3-kinase B in astrocytes. *J Biol Chem* 274:14734–14742

- Czapiga M and Colton CA (1999) Function of microglia in organotypic slice cultures. *J Neurosci Res* 56:644–651
- Di Virgilio F (1995) The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. *Immunol Today* 16:524–528
- Di Virgilio F, Sanz JM, Chiozzi P, Falzoni S (1999) The P2Z/P2X<sub>7</sub> receptor of microglial cells: a novel immunomodulatory receptor. *Prog Brain Res* 120:355–368
- Duan S, Anderson CM, Keung EC, Chen Y, Chen Y, Swanson RA (2003) P2X<sub>7</sub> receptor-mediated release of excitatory amino acids from astrocytes. *J Neurosci* 23:1320–1328
- Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A (1995) Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X purinoceptors). *Mol Pharmacol* 48:178–183
- Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K (1997) Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoceptor by selectively targeting NF-kappaB p65. *J Cell Biol* 139:1635–1643
- Ferrari D, Los M, Bauer MK, Vandenberghe P, Wesselborg S, Schulze-Osthoff K (1999) P2Z purinoceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. *FEBS Lett* 447:71–75
- Fields RD, Stevens B (2000) ATP: an extracellular signalling molecule between neurons and glia. *Trends Neurosci* 23:625–633
- Frantseva MV, Kokarovtseva L, Perez Velazquez JL (2002) Hypoxia/glucose deprivation-induced brain damage depends on specific gap-junctional coupling. *J Cereb Blood Flow Metab* 22:453–462
- Hide I, Tanaka M, Inoue A, Nakajima K, Kohsaka S, Inoue K, Nakata Y (2000) Extracellular ATP triggers tumor necrosis factor- $\alpha$  release from rat microglia. *J Neurochem* 75:965–972.
- Humphreys BD, Rice J, Kertesz SB, Dwyer GR (2000) Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X<sub>7</sub> nucleotide receptor. *J Biol Chem* 275:26792–26798
- Juranyi Z, Sperlagh B, Vizi ES (1999) Involvement of P2 purinoceptors and the nitric oxide pathway in [<sup>3</sup>H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. *Brain Res* 823:183–190
- Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. *Pharmacol Rev* 53, 107–18
- Le Feuvre R, Brough D, Rothwell N (2002) Extracellular ATP and P2X<sub>7</sub> receptors in neurodegeneration. *Eur J Pharmacol* 447:261–269
- Le Feuvre RA, Brough D, Touzani O, Rothwell NJ (2003) Role of P2X<sub>7</sub> Receptors in Ischemic and Excitotoxic Brain Injury. *J Cereb Blood Flow Metab* 23:381–384
- Murgia M, Hanau S, Pizzo P, Ripa M, Di Virgilio F (1993) Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. *J. Biol. Chem.* 268:8199–8203
- Nicke A, Baumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, Schmalzing G (1998) P2X<sub>1</sub> and P2X<sub>3</sub> receptors form stable trimers: a novel structural motif of ligand-gated ion channels. *EMBO J* 17:3016–3028
- Nieber K, Eschke D, Brand A (1999) Brain hypoxia: effects of ATP and adenosine. *Prog Brain Res* 120:287–297
- North RA (2002) Molecular physiology of P2X receptors. *Physiol Rev* 82:1013–1067
- North, RA and Barnard EA (1997) Nucleotide receptors. *Curr Opin Neurobiol.* 7:346–357
- North RA and Surprenant A (2000) Pharmacology of cloned P2X receptors. *Annu Rev Pharmacol Toxicol* 40:563–580
- Parvathenani LK, Tertysnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R (2003) P2X<sub>7</sub> mediates super oxide production in primary microglia and is up regulated in a transgenic mouse model of Alzheimer's disease. *J Biol Chem* 278:13309–13317
- Pellegrini-Giampietro DE, Peruginelli F, Meli E, Cozzi A, Albani-Torregrossa S, Pellicciari R, Moroni F (1999) Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. *Neuropharmacol* 38, 1607–1619
- Phillis JW, O'Regan MH, Perkins LM, (1993) Adenosine 5'-triphosphate release from the normoxic and hypoxic *in vivo* rat cerebral cortex. *Neurosci Lett* 151:94–96
- Pringle AK, Iannotti F, Wilde GJ, Chad JE, Seeley PJ, Sundstrom LE (1997) Neuroprotection by both NMDA and non-NMDA receptor antagonists in *in vitro* hypoxia/glucose deprivation. *Brain Res* 755:36–46
- Sanz JM and Di Virgilio F (2000) Kinetics and mechanism of ATP-dependent IL-1 beta release from microglial cells. *J Immunol* 164:4893–4898
- Schulze-Lohoff E, Hugo C, Rost S, Arnold S, Gruber A, Brune B, Sterzel RB (1998) Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X<sub>7</sub> receptors. *Am J Physiol* 275:F962–971
- Sperlagh B, Kofalvi A, Deuchars J, Atkinson L, Milligan CJ, Buckley NJ, Vizi ES (2002) Involvement of P2X<sub>7</sub> receptors in the regulation of neurotransmitter release in the rat hippocampus. *J Neurochem* 81:1196–1211
- Stoppini L, Buchs PA, Muller D (1991) A simple method for organotypic cultures of nervous tissue. *J Neurosci Methods* 37:173–182
- Vizi ES (2000) Role of high-affinity receptors and membrane transporters in non-synaptic communication and drug action in the central nervous system. *Pharmacol Rev* 52:63–89